First Mercantile Trust Co. Cuts Position in Spark Therapeutics Inc (ONCE)

First Mercantile Trust Co. cut its stake in Spark Therapeutics Inc (NASDAQ:ONCE) by 53.5% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 525 shares of the biotechnology company’s stock after selling 605 shares during the period. First Mercantile Trust Co.’s holdings in Spark Therapeutics were worth $60,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System grew its position in Spark Therapeutics by 1.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 17,916 shares of the biotechnology company’s stock worth $2,040,000 after acquiring an additional 220 shares in the last quarter. SG Americas Securities LLC lifted its stake in Spark Therapeutics by 7.0% in the fourth quarter. SG Americas Securities LLC now owns 4,806 shares of the biotechnology company’s stock worth $188,000 after purchasing an additional 313 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in Spark Therapeutics by 10.7% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 4,117 shares of the biotechnology company’s stock worth $469,000 after purchasing an additional 399 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Spark Therapeutics by 16.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,460 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 485 shares during the last quarter. Finally, Sterling Investment Advisors Ltd. bought a new stake in Spark Therapeutics in the first quarter worth $68,000.

Several research firms have weighed in on ONCE. Zacks Investment Research downgraded shares of Spark Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, April 24th. Cantor Fitzgerald reissued a “buy” rating and issued a $80.00 price target on shares of Spark Therapeutics in a research note on Sunday, February 17th. SunTrust Banks downgraded shares of Spark Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 25th. Mizuho downgraded shares of Spark Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, February 25th. Finally, Barclays downgraded shares of Spark Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $74.00 to $115.00 in a research note on Monday, March 25th. Eighteen investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Spark Therapeutics has an average rating of “Hold” and a consensus target price of $78.45.

Shares of NASDAQ:ONCE opened at $108.84 on Friday. The stock has a market cap of $4.19 billion, a PE ratio of -51.58 and a beta of 2.48. The company has a quick ratio of 5.59, a current ratio of 5.94 and a debt-to-equity ratio of 0.18. Spark Therapeutics Inc has a 12 month low of $34.53 and a 12 month high of $114.20.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Tuesday, February 19th. The biotechnology company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.89). The firm had revenue of $13.15 million for the quarter, compared to the consensus estimate of $26.76 million. Spark Therapeutics had a negative net margin of 124.33% and a negative return on equity of 16.68%. The business’s revenue was up 47.9% on a year-over-year basis. During the same period last year, the company posted ($1.63) earnings per share. On average, equities analysts anticipate that Spark Therapeutics Inc will post -4.31 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “First Mercantile Trust Co. Cuts Position in Spark Therapeutics Inc (ONCE)” was originally posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/24/first-mercantile-trust-co-cuts-position-in-spark-therapeutics-inc-once.html.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

Featured Article: Why do company’s buyback their stock?

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.